The core activity of my group is around the development of new therapies targeting misfolded proteins involved in several neurodegenerative disorders, with a focus on Alzheimer’s and Parkinson’s diseases. We are designing, performing and analyzing pharmacology treatment studies for different projects, and we are constantly developing new models and methods of analysis to accurately predict the efficacy of drug candidates that will be tested in patients. We are using multidisciplinary approaches, working in close collaboration with protein chemists and pathologists at Biogen and in collaboration with academic laboratories.

I have been part of the neurology research group at Biogen since 2005. My area of expertise is Alzheimer’s disease, from a molecular, pathological and drug discovery perspective. My Ph.D. work focused on tau proteins, and I completed an academic postdoc at Mount Sinai School of Medicine and an industry postdoc at Elan Pharmaceuticals.

Education

  • Postdoctoral Fellow, Elan Pharmaceuticals, South San Francisco, CA, 2001–2005
  • Postdoctoral Fellow, Mount Sinai School of Medicine, New York, NY, 1999–2001
  • Ph.D., Neurology, University of Lille, France, 1995–1998

Selected Publications

See more scientists